Effects of somatostatin analogs on glucose homeostasis in rats

Journal of Endocrinology

Volumn 212, Issue 1, 2012, Pages 49-60

  Schmid, Herbert A ^a   Brueggen, Josef ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON; GLUCOSE; INSULIN; OCTREOTIDE; PASIREOTIDE; SOMATOMEDIN C; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 4; SOMATOSTATIN RECEPTOR 5;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG FORMULATION; DRUG MEGADOSE; GLUCAGON BLOOD LEVEL; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; RAT; SOMATIC DELUSION;

ANIMALS; BLOOD GLUCOSE; GLUCAGON; HOMEOSTASIS; HYPERGLYCEMIA; INSULIN; INSULIN-LIKE GROWTH FACTOR I; MALE; OCTREOTIDE; RATS; RATS, INBRED LEW; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN;

EID: 83455211387     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-11-0224     Document Type: Article

References (35)

1. Baldelli R, Battista C, Leonetti F, Ghiggi M-R, Ribaudo M-C, Paoloni A, D'Amico E, Ferretti E, Baratta R, Liuzzi A et al. 2003 Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment. Clinical Endocrinology 59 492-499.
2. Barkan AL, Burman P, Clemmons DR, Drake WM, Gagel RF, Harris PE, Trainer PJ, van der Lely AJ & Vance ML 2005 Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. Journal of Clinical Endocrinology and Metabolism 90 5684-5691.
3. Boscaro M, Ludlam WH, Atkinson B, Glusman JE, Petersenn S, Reincke M, Snyder P, Tabarin A, Biller BM, Findling J et al. 2009 Treatment of pituitary dependent Cushing's disease with the multi-receptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. Journal of Clinical Endocrinology and Metabolism 94 115-122.
4. Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J & Guillemin R 1973 Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 179 77-79.
5. Bruns C, Lewis I, Briner U, Meno-Tetang G & Weckbecker G 2002 SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. European Journal of Endocrinology 146 707-716.
6. Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Schoenherr U, Mills D, Salgado LR & Biller BM 2011 Pasireotide (SOM230) demonstrates efficacy in patients with Cushing disease: results from a large, randomized-dose, double-blind, phase III study. Endocrine Reviews 32 abst OR09-6.
7. Drucker DJ 2007 The role of gut hormones in glucose homeostasis. Journal of Clinical Investigation 117 24-32.
8. Fagan SP, Azizzadeh A, Moldovan S, Ray MK, Adrian TE, Ding X, Coy DH & Brunicardi FC 1998 Insulin secretion is inhibited by subtype five somatostatin receptor in the mouse. Surgery 124 254-258.
9. Farrall A, Ruffin M, Wetli-Hermosillo K & Petersenn S 2010 Long-term treatment of acromegaly with pasireotide (SOM230): results from a phase II extension study. Endocrine Reviews 31 (3 Supplement 1) S856 (abst OR16-5).
10. Fleseriu M 2011 Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review. Pituitary 14 184-193.
11. Hauge-Evans AC, King AJ, Carmignac D, Richardson CC, Robinson IC, Low MJ, Christie MR, Persaud SJ & Jones PM 2009 Somatostatin secreted by islet delta-cells fulfills multiple roles as a paracrine regulator of islet function. Diabetes 58 403-411.
12. Henry RR, Mudaliar S, Wetli-Hermosillo K, Ligueros-Saylan M, Chenji S & Golor G 2011 Mechanism and management of hyperglycemia associated with pasireotide: results from studies in healthy volunteers. Endocrine Reviews 32 abst P3-274.
13. Hofland LJ & Lamberts SW 2003 The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocrine Reviews 24 28-47.
14. Kumar U, Sasi R, Suresh S, Patel A, Thangaraju M, Metrakos P, Patel SC & Patel YC 1999 Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis. Diabetes 48 77-85.
15. Kvols L, Oberg K, O'Dorisio TM, Mohideen P, De Herder W, Hughes G, Zhang Y, Arnold R, Anthony L & Wiedenmann B 2010 On behalf of the Pasireotide Carcinoid Study Group. Efficacy, safety and pharmacokinetic results from a phase II study of pasireotide (SOM230) in the treatment of patients with metastatic NETs refractory or resistant to octreotide LAR. Neuroendocrinology 92 abst C57.
16. Ma P, Wang Y, Van Der Hoek J, Nedelman J, Schran H, Tran L-L & Lamberts SW 2005 Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly. Clinical Pharmacology and Therapeutics 78 69-80.
17. Mitra SW, Mezey E, Hunyady B, Chamberlain L, Hayes E, Foor F, Wang Y, Schonbrunn A & Schaeffer JM 1999 Colocalization of somatostatin receptor sst5 and insulin in rat pancreatic beta-cells. Endocrinology 140 3790-3796.
18. Norman M, Moldovan S, Seghers V, Wang XP, DeMayo FJ & Brunicardi FC 2002 Sulfonylurea receptor knockout causes glucose intolerance in mice that is not alleviated by concomitant somatostatin subtype receptor 5 knockout. Annals of Surgery 235 767-774.
19. Petersenn S, Schopohl J, Barkan A, Mohideen P, Colao A, Abs R, Buchelt A, Ho Y-Y, Hu K, Farrall AJ et al. 2010 Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. Journal of Clinical Endocrinology and Metabolism 95 2781-2789.
20. Rizza R, Verdonk C, Miles J, Service FJ, Haymond M & Gerich J 1979 Somatostatin does not cause sustained fasting hyperglycemia in man. Hormone and Metabolic Research 11 643-644.
21. Schmid HA 2008 Pasireotide (SOM230): development, mechanism of action and potential applications. Molecular and Cellular Endocrinology 286 69-74.
22. Schmid HA 2010 Pasireotide (SOM230) as a potential treatment for endocrine and non-endocrine tumors. Current Drug Therapy 5 301-311.
23. Schmid HA & Schoeffter P 2004 Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology 80 (Supplement 1) 47-50.
24. Schmid HA & Silva AP 2005 Short- and long-term effects of octreotide and SOM230 on GH, IGF-I, ACTH, corticosterone and ghrelin in rats. Journal of Endocrinological Investigation 28 (11 Supplement) 28-35.
25. Schmid HA & Silva AP 2006 Short-term and long-term effects of pasireotide (SOM230) and octreotide on plasma glucose, insulin and glucagon in rats. Annual Meeting of the Endocrine Society. Boston, MA, USA, 24-27 June abst P2-175.
26. Silva AP, Schoeffter P, Weckbecker G, Bruns C & Schmid HA 2005 Regulation of CRH-induced secretion of ACTH and corticosterone by SOM230 in rats. European Journal of Endocrinology 153 R7-R10.
27. Singh V, Brendel MD, Zacharias S, Mergler S, Jahr H, Wiedenmann B, Bretzel RG, Plöckinger U & Strowski MZ 2007a Characterization of somatostatin receptor subtype-specific regulation of insulin and glucagon secretion: an in vitro study on isolated human pancreatic islets. Journal of Clinical Endocrinology and Metabolism 92 673-680.
28. Singh V, Grözinger C, Nowak KW, Zacharias S, Göncz E, Pless G, Sauer IM, Eichhorn I, Pfeiffer-Guglielmi B, Hamprecht B et al. 2007b Somatostatin receptor subtype-2-deficient mice with diet-induced obesity have hyperglycemia, nonfasting hyperglucagonemia, and decreased hepatic glycogen deposition. Endocrinology 148 3887-3899.
29. Steffin B, Gutt B, Bidlingmaier M, Dieterle C, Oltmann F & Schopohl J 2006 Effects of the long-acting somatostatin analogue Lanreotide Autogel on glucose tolerance and insulin resistance in acromegaly. European Journal of Endocrinology 155 73-78.
30. Strowski MZ, Kohler M, Chen HY, Trumbauer ME, Li Z, Szalkowski D, Gopal-Truter S, Fisher JK, Schaeffer JM, Blake AD et al. 2003 Somatostatin receptor subtype 5 regulates insulin secretion and glucose homeostasis. Molecular Endocrinology 17 93-106.
31. Tirone TA, Norman MA, Moldovan S, DeMayo FJ, Wang XP & Brunicardi FC 2003 Pancreatic somatostatin inhibits insulin secretion via SSTR-5 in the isolated perfused mouse pancreas model. Pancreas 26 e67-e73.
32. Van Op den Bosch J, Adriaensen D, Van Nassauw L & Timmermans JP 2009 The role(s) of somatostatin, structurally related peptides and somatostatin receptors in the gastrointestinal tract: a review. Regulatory Peptides 156 1-8.
33. Weckbecker G, Briner U, Lewis I & Bruns C 2002 SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs. Endocrinology 143 4123-4130.
34. Xuan S, Kitamura T, Nakae J, Politi K, Kido Y, Fisher PE, MorroniM, Cinti S, White MF, Herrera PL et al. 2002 Defective insulin secretion in pancreatic beta cells lacking type 1 IGF receptor. Journal of Clinical Investigation 110 1011-1019.
35. Zambre Y, Ling Z, Chen MC, Hou X, Woon CW, Culler M, Taylor JE, Coy DH, Van Schravendijk C, Schuit F et al. 1999 Inhibition of human pancreatic islet insulin release by receptor-selective somatostatin analogs directed to somatostatin receptor subtype 5. Biochemical Pharmacology 57 1159-1164.